Clinical Trials Logo

Filter by:
NCT ID: NCT03734653 Active, not recruiting - Prostate Cancer Clinical Trials

Testosterone Therapy in Castration Resistant Prostate Cancer

Start date: January 18, 2019
Phase: Early Phase 1
Study type: Interventional

This is an open-labeled, single-arm, interventional pilot study. It is being done to determine the feasibility of the administration of transdermal testosterone alternating with enzalutamide, as well as the safety and efficacy.

NCT ID: NCT03734393 Active, not recruiting - Hiv Clinical Trials

HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients

Start date: January 4, 2019
Phase: N/A
Study type: Interventional

The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications

NCT ID: NCT03734237 Active, not recruiting - Influenza Clinical Trials

A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD

PAIVED
Start date: November 6, 2018
Phase: Phase 4
Study type: Interventional

A total of 18,000 eligible subjects (or 6,000 subject distributed evenly between the 3 study arms) will be enrolled. Eligible subjects will be randomized in 1:1:1 (cell-culture-based vaccine, the recombinant vaccine, or the egg-based vaccine) over four influenza seasons (2018-2019, 2019-2020, 2020-2021, and 2021-2022).

NCT ID: NCT03734107 Active, not recruiting - Clinical trials for Type 1 Diabetes Mellitus

Improving Health Communication During the Transition From Pediatric to Adult Diabetes Care

Start date: November 6, 2018
Phase: N/A
Study type: Interventional

Adolescents and young adults (AYAs; ages 17-23) with type 1 diabetes are at high risk for negative health outcomes, including poor glycemic control and disengagement from the health care system. The deterioration of glycemic control occurs in parallel with the assumption of independent self-care skills and preparation for adult diabetes care. Effective communication between AYAs and health care providers may be a critical contributor to diabetes self-care skills during the transition to adult diabetes care and related glycemic control. This research will attempt to better prepare adolescents and young adults for adult diabetes care by delivering innovative intervention content focused on both health communication skills and transition readiness skills. The investigators aim to leverage innovative technologies to improve developmentally-appropriate communication skills related to planning for clinic visits, disclosing and discussing diabetes-related concerns, and optimizing glucose data review in preparation for adult diabetes care. Adolescents and young adults with type 1 diabetes (ages 17-23) who are planning to transition to adult diabetes care within the next 6-8 months will be enrolled in the study and randomized to either the intervention group or a standard care control group. Medical, communication and psychosocial data (including A1c, glucose monitoring frequency, communication quality, health care engagement, depressive symptoms) will be collected from adolescent and young adult participants and health care providers at baseline and two follow-up time points, approximately 4 months post-baseline and approximately 8-12 months post-baseline after the transfer to adult diabetes care. This intervention has the potential to improve diabetes self-care skills, including engagement with health care providers, and glycemic control in AYAs with type 1 diabetes during the vulnerable period of transfer to adult diabetes care. The results of this work will inform best practices for the transition to adult diabetes care and can be translated into clinical care.

NCT ID: NCT03734055 Active, not recruiting - Quality of Life Clinical Trials

Peer Approaches to Lupus Self-management

PALS
Start date: November 30, 2018
Phase: N/A
Study type: Interventional

The Peer Approaches to Lupus Self-Management (PALS) study is a randomized, controlled in which 360 African American women with lupus will be recruited from the MUSC SLE database (60 mentors and 300 mentees). The peer mentoring intervention (patients will be matched with peer mentors who are considered competent in the management of their condition to provide modeling and reinforcement to participants) will occur by telephone for approximately 60 minutes every two weeks for 24 weeks. All participants will be assessed at baseline, mid-intervention (12 weeks post-enrollment), immediately following the intervention (24 weeks post-enrollment), and 12 months post-enrollment. The study will last 60 months with recruitment and enrollment over 48 months, 6 months for intervention delivery and 6 months for data analysis.

NCT ID: NCT03734029 Active, not recruiting - Breast Cancer Clinical Trials

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Start date: December 27, 2018
Phase: Phase 3
Study type: Interventional

This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before. Participants' cancer: - Cannot be removed by an operation - Has spread to other parts of the body

NCT ID: NCT03733626 Active, not recruiting - Clinical trials for Degenerative Disc Disease

Clinical Outcomes Associated With the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease

ViviGen
Start date: March 19, 2019
Phase: N/A
Study type: Interventional

The objective of this study is to perform a prospective, randomized, controlled clinical trial to compare radiographic fusion rates and patient reported outcomes, including pain and function preoperatively and postoperatively, using Depuy ViviGen® Cellular Bone Matrix mixed with cortical/cancellous allograft in conjunction with an approved Depuy Synthes pedicle screw system compared to autograft mixed with cortical/cancellous allograft in conjunction with the same DePuy Synthes pedicle screw system used for a one or two - level posterolateral lumbar fusion.

NCT ID: NCT03732950 Active, not recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

Start date: March 6, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating participants with ovarian cancer that has come back after previous treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03732820 Active, not recruiting - Clinical trials for Metastatic Castration-resistant Prostate Cancer

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Start date: October 31, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

NCT ID: NCT03732794 Active, not recruiting - Clinical trials for Persistent Atrial Fibrillation

AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

ICE-AFIB
Start date: January 30, 2019
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate the safety and effectiveness of the AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with Left Atrial Appendage (LAA) exclusion using the AtriClip device.